实性部分肿瘤体积倍增时间对部分实性或实性肺癌的预后影响
本研究纳入258例影像学淋巴结阴性、部分实性或实性非小细胞肺癌患者,术前至少两次CT间隔超过30天,行根治性肺叶切除及系统淋巴结清扫。多变量分析显示全肿瘤体积倍增时间和实性部分体积倍增时间(SVDT)均显著影响无复发生存,SVDT截断值215天,5年无复发生存率在SVDT>215天组为85.7%,<215天组为43.0%。结论认为计算SVDT有助于预测术后生存结局。
要点
- SVDT是淋巴结阴性部分实性或实性NSCLC术后无复发生存的独立预后因素。
- SVDT截断值215天,>215天组5年无复发生存率85.7%,<215天组43.0%。
- 全肿瘤VDT、SVDT、实性部分大小、全肿瘤大小及合并症均显著影响无复发生存。
核心结论
- 在影像学淋巴结阴性的部分实性或实性NSCLC患者中,计算实性部分肿瘤体积倍增时间对预测术后生存结局高度有用。
研究设计与样本
- 回顾性纳入258例影像学淋巴结阴性、部分实性或实性NSCLC患者,术前至少2次CT间隔超过30天,随后行根治性肺叶切除及系统淋巴结清扫,时间范围为2012年1月至2015年12月。
- 采用Cox比例风险回归模型对无复发生存进行单变量和多变量分析。
主要发现
- 全肿瘤体积倍增时间平均375天,实性部分体积倍增时间(SVDT)平均458天。
- 多变量分析显示全肿瘤VDT(P=0.003)、SVDT(P<0.001)、实性部分肿瘤大小、全肿瘤大小及合并症显著影响无复发生存。
- 通过受试者工作特征曲线确定SVDT预测复发的截断值为215天。
- SVDT>215天与SVDT<215天患者的5年无复发生存率分别为85.7%和43.0%(P<0.001)。
关键数值与推荐
- SVDT预测复发的截断值为215天。
- SVDT>215天患者5年无复发生存率85.7%,SVDT<215天患者为43.0%(P<0.001)。
临床怎么用
- 对于影像学淋巴结阴性的部分实性或实性NSCLC患者,可分别计算全肿瘤VDT和实性部分VDT以辅助术后生存风险评估。
- SVDT低于215天提示复发风险较高,可能需更密切的术后随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The measurement of part-solid and whole tumour sizes in patients with non-small-cell lung cancer (NSCLC) using computed tomography (CT) has been widely accepted for assessing clinical outcomes. Although the volume doubling time (VDT) of a tumour is useful for distinguishing high-risk nodules from low-risk ones, it remains to be clarified whether separate calculation of whole-tumour VDT and solid-part tumour VDT (SVDT) greatly affects the survival rate of patients with radiologically node-negative part-solid or solid NSCLC. METHODS: The study included 258 patients with NSCLC who had radiologically node-negative, part-solid or solid tumours and who had at least 2 preoperative CT scans taken more than 30 days apart followed by radical lobectomy and systemic lymph node dissection between January 2012 and December 2015. Univariable and multivariable analyses of recurrence-free survival were performed using the Cox proportional hazards regression model. RESULTS: The mean whole-tumour VDT and SVDT were 375 and 458 days, respectively. Multivariable analyses demonstrated that whole-tumour VDT (P = 0.003), SVDT (P < 0.001), solid-part tumour size, whole-tumour size and comorbidities significantly affected the recurrence-free survival. Using the receiver operating characteristic curve, the cut-off value of the SVDT for recurrence was 215 days, and the 5-year recurrence-free survival rates for patients with SVDT >215 days and those with SVDT <215 days were 85.7% and 43.0%, respectively (P < 0.001). CONCLUSION: The calculation of SVDT in patients with node-negative, part-solid or solid NSCLC is highly useful for predicting postoperative survival outcomes.
引用
- Setojima Y, Shimada Y, Tanaka T, et al. Prognostic impact of solid-part tumour volume doubling time in patients with radiological part-solid or solid lung cancer. Eur J Cardiothorac Surg. 2020. PMID: 31746987. doi:10.1093/ejcts/ezz305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。